New Zealand markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
143.80-2.27 (-1.55%)
At close: 04:00PM EDT
141.00 -2.80 (-1.95%)
After hours: 05:53PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
1,828,292
1,828,292
1,037,418
844,287
492,853
Cost of revenue
310,406
310,406
168,817
140,144
78,052
Gross profit
1,517,886
1,517,886
868,601
704,143
414,801
Operating expenses
Research development
1,004,415
1,004,415
883,015
792,156
654,819
Selling general and administrative
795,646
795,646
770,658
620,639
588,420
Total operating expenses
1,800,061
1,800,061
1,653,673
1,412,795
1,243,239
Operating income or loss
-282,175
-282,175
-785,072
-708,652
-828,438
Interest expense
121,221
121,221
155,968
143,021
84,496
Total other income/expenses net
-125,682
-125,682
-210,761
-2,050
45,525
Income before tax
-433,517
-433,517
-1,126,993
-852,144
-855,600
Income tax expense
6,725
6,725
4,163
680
2,681
Income from continuing operations
-440,242
-440,242
-1,131,156
-852,824
-858,281
Net income
-440,242
-440,242
-1,131,156
-852,824
-858,281
Net income available to common shareholders
-440,242
-440,242
-1,131,156
-852,824
-858,281
Basic EPS
-4.11
-3.52
-9.30
-7.20
-7.46
Diluted EPS
-4.11
-3.52
-9.30
-7.20
-7.46
Basic average shares
124,321
124,906
121,689
118,451
114,986
Diluted average shares
124,321
124,906
121,689
118,451
114,986